Drug Most Volatile Stocks: Raptor Pharmaceutical (NASDAQ:RPTP), KaloBios Pharmaceuticals (NASDAQ:KBIO), Ventrus Biosciences (NASDAQ:VTUS), Tonix Pharmaceuticals Holding (NASDAQ:TNXP), Auspex Pharmaceuticals (NASDAQ:ASPX)

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) announced that company management will participate in upcoming investor conference in June: Wells Fargo Healthcare Conference – Boston, June 17, 2014 at 8:50 a.m. EDT. A live audio webcast and archive of the presentation will be available on the company website atwww.raptorpharma.com. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) weekly performance is 33.12%. On last trading day company shares ended up $10.53. Analysts mean target price for the company is $21.00. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) distance from 50-day simple moving average (SMA50) is 24.69%.

On May 29, KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) was a big mover last session with its shares rising over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has gained over 12% since May 19, according to Zack. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) shares advanced 12.70% in last trading session and ended the day on $2.13. Its return on assets is -77.70%. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) quarterly performance is -34.46 %.

On June 9, Ventrus Biosciences, Inc. (NASDAQ:VTUS) announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) in connection with the upcoming annual meeting of Ventrus stockholders. The Company also announced that it is commencing the mailing of the definitive proxy materials to its stockholders. Ventrus Biosciences Inc (NASDAQ:VTUS) shares moved up 1.10% in last trading session and was closed at $1.38, while trading in range of $1.29 – $1.41. Ventrus Biosciences Inc (NASDAQ:VTUS) year to date (YTD) performance is -63.87%.

Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to develop TNX-102 SL, a proprietary sublingual formulation of cyclobenzaprine HCl, for the treatment of post-traumatic stress disorder (PTSD). PTSD is a serious mental illness triggered by a traumatic event and is believed to affect more than eight million U.S. adults. Under this IND, Tonix will be able to move forward in the third quarter of this year with its planned U.S.-based Phase 2 clinical trial designed to evaluate the safety and efficacy of TNX-102 SL in patients with PTSD. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ended the last trading day at $10.70. Company weekly volatility is calculated as 6.75% and price to cash ratio as 2.14. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) showed a positive weekly performance of 8.19%.

On May 13, 2014, Auspex Pharmaceuticals, Inc (NASDAQ:ASPX) a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced its financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, Auspex reported a net loss of $10.1 million versus a net loss of $2.3 million in the comparable period in 2013. The increase in the net loss was largely a result of increased development activities for SD-809, higher general and administrative costs incurred as a public company, and a $3.6 million one-time, non-cash charge for the fair value of preferred stock warrants liability upon the completion of our IPO. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) weekly performance is 11.13%. On last trading day company shares ended up $22.06. Analysts mean target price for the company is $38.75. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) distance from 50-day simple moving average (SMA50) is -0.89%.